

## 15450 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

urinary tract infections, ulcerative colitis, pneumonia, staphylococcus infections, streptococcus infections, eye infections, yaws, and gonorrhea.

In Central America, a competitive brand marketed by McKesson is recommended for whooping cough.

In the United States, the Parke-Davis product carries a long list of contraindications, warnings, and adverse reactions. Perhaps the most alarming of these include aplastic anemia and other serious or fatal diseases of the blood-forming system.

In Mexico, the Parke-Davis product carries only a limited list of warnings. In Central America, no contraindications or warnings are given, and no adverse reactions are disclosed.

The McKesson product statement discloses a few hazards in Central America but none in Colombia and Ecuador.

In the case of tetracycline, marketed by Lederle under the name of Achromycin, numerous adverse reactions are given in the United States, a few in Mexico and Brazil, and none in the Central American countries.

For Squibb's amphotericin B, marketed as Fungizone, physicians in this country are told that this valuable but potentially toxic antibiotic should be used primarily for the treatment of progressive and potentially fatal forms of fungal infections. No such warning is listed in the Latin American promotion.

Schering's Garamycin carries roughly the same indications in the United States and Latin America, but the warnings are minimized